Litigation Details for In Re: Opana ER Antitrust Litigation (N.D. Ill. 2014)
✉ Email this page to a colleague
In Re: Opana ER Antitrust Litigation (N.D. Ill. 2014)
Docket | ⤷ Sign Up | Date Filed | 2014-12-12 |
Court | District Court, N.D. Illinois | Date Terminated | 2022-07-01 |
Cause | 28:1331 Federal Question | Assigned To | Matthew F. Kennelly |
Jury Demand | Defendant | Referred To | |
Parties | ALL PLAINTIFFS AND DEFENDANTS | ||
Patents | 6,022,539; 6,228,398; 6,294,195; 6,495,155; 7,229,636; 7,276,250; 7,404,489; 7,718,640; 7,811,560; 7,851,482; 7,879,349; 8,003,353; 8,075,872; 8,114,383; 8,192,722; 8,309,060; 8,309,122; 8,329,216; 8,338,395; 8,808,737; 8,871,779; 8,940,714; 9,119,876; 9,295,657; 9,375,478; 9,415,007; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223; RE39,941 | ||
Attorneys | John Paul Bjork | ||
Firms | Kirkland & Ellis, LLP | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in In Re: Opana ER Antitrust Litigation
Biologic Drugs cited in In Re: Opana ER Antitrust Litigation
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for In Re: Opana ER Antitrust Litigation (N.D. Ill. 2014)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2015-05-04 | 102 | for what ultimately issued as U.S. Patent No. 7,276,250 patent entitled “Sustained release formulations…the Orange Book patents because: (1) no patents exist on the brand drug; (2) the patents have expired;…artificial act” of patent infringement, permitting the patent owner to file a patent infringement suit…ER. This patent is expected to provide patent protection until November 2023. The new patent will be listed…limitations on the types of patents that can be listed. Only drug substance patents (active ingredient), drug | External link to document | |
2016-02-10 | 151 | patent”), No. 5,662,933 (the “‘933 patent”), and No. 7,276,250 …purchased the rights to four patents — U.S. Patent No. 5,128,143 (the “143 patent”), No. 5,958,456 (the …of any unexpired patents listed in the Orange Book; or (IV) that any unexpired patents listed in the Orange…artificial act” of patent infringement, permitting the brand company to file a patent infringement suit… ‘143 patent in the Orange Book as covering Opana ER, and later added the ‘456 and ‘933 patents. | External link to document | |
2016-02-25 | 162 | “‘456 patent”), No. 5,662,933 (the “‘933 patent”), and No. 7,276,250 (the “‘250 patent”) (collectively… rights to four patents — U.S. Patent No. 5,128,143 (the “‘143 patent”), No. …expiration of the Penwest Patents, and Endo sued each for patent infringement. RAC ¶¶ 84-109…enforceability of the ‘933 and ‘456 patents, as well as the ‘250 patent, which Endo had not even accused…agreement to settle ongoing patent infringement Case: 1:14-cv-10150 Document | External link to document | |
2016-03-02 | 164 | for what ultimately issued as U.S. Patent No. 7,276,250 patent entitled “Sustained release formulations…the Orange Book patents because: (1) no patents exist on the brand drug; (2) the patents have expired;…artificial act” of patent infringement, permitting the patent owner to file a patent infringement suit…ER. This patent is expected to provide patent protection until November 2023. The new patent will be listed…limitations on the types of patents that can be listed. Only drug substance patents (active ingredient), drug | External link to document | |
2020-04-29 | 562 | Exclusive License USA 6,022,539 June 3, 2019 …issued patents, 36 U.S. patent applications pending, 157 foreign issued patents and 72 foreign patent applications… by patent rights or have limited patent life and will soon lose patent protection. Loss of patent protection…five patents relating to VASOSTRICT® by the U.S. Patent and Trademark Office (PTO). These patents expire…243 U.S. issued patents, 64 U.S. patent applications pending, 551 foreign issued patents, and 150 foreign | External link to document | |
2020-04-29 | 581 | Exclusive License USA 6,022,539 June 3, 2019 …issued patents, 36 U.S. patent applications pending, 157 foreign issued patents and 72 foreign patent applications… by patent rights or have limited patent life and will soon lose patent protection. Loss of patent protection…five patents relating to VASOSTRICT® by the U.S. Patent and Trademark Office (PTO). These patents expire…243 U.S. issued patents, 64 U.S. patent applications pending, 551 foreign issued patents, and 150 foreign | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |